Joseph R Mikhael, MD from the Mayo Clinic, Scottsdale, AZ talks about new drugs being used for the treatment of multiple myeloma (MM), and where they fit in the current treatment landscape. He discusses how drugs like elotuzumab can be used in the early relapsed setting, whilst daratumumab is more suitbale for 3rd line therapy. He also talks about anit-CD38 therapies being used much earlier, perhaps even as front-line therapy or in combination with other drugs.
Recorded at the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL.
To see more videos go to http://www.vjhemonc.com/